All In Biotech

Drug Trial Radar · NCT07114315

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

A Phase II Clinical Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Sep 19, 2025

Primary completion

Aug 2027

Study completion Aug 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Aug 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer. Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.

Conditions

  • Pancreatic Cancer

Interventions

  • AK112Drug

    Following a predefined dose and date.

  • AK130Drug

    Following a predefined dose and date.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 30 days after the last dose of study drug or starting new anti-cancer therapy.
  2. Objective Response Rate (ORR)Time frame: Through study completion, an average of 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.